TY - JOUR AU - Coudert, B. P. AU - Arnould, L. AU - Moreau, L. AU - Chollet, P. AU - Weber, B. AU - Vanlemmens, L. PY - 2006 DA - 2006// TI - Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial JO - Ann Oncol VL - 17 UR - https://doi.org/10.1093/annonc/mdj096 DO - 10.1093/annonc/mdj096 ID - Coudert2006 ER - TY - JOUR AU - Coudert, B. P. AU - Largillier, R. AU - Arnould, L. AU - Chollet, P. AU - Campone, M. AU - Coeffic, D. PY - 2007 DA - 2007// TI - Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.9994 DO - 10.1200/JCO.2006.09.9994 ID - Coudert2007 ER - TY - JOUR AU - Kuerer, H. M. AU - Newman, L. A. AU - Smith, T. L. AU - Ames, F. C. AU - Hunt, K. K. AU - Dhingra, K. PY - 1999 DA - 1999// TI - Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy JO - J Clin Oncol VL - 17 ID - Kuerer1999 ER - TY - JOUR AU - Végran, F. AU - Boidot, R. AU - Coudert, B. AU - Fumoleau, P. AU - Arnould, L. AU - Garnier, J. PY - 2009 DA - 2009// TI - Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma JO - Br J Cancer VL - 101 UR - https://doi.org/10.1038/sj.bjc.6605310 DO - 10.1038/sj.bjc.6605310 ID - Végran2009 ER - TY - JOUR AU - Liu, J. C. AU - Voisin, V. AU - Bader, G. D. AU - Deng, T. AU - Pusztai, L. AU - Symmans, W. F. PY - 2012 DA - 2012// TI - Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer JO - Proc Natl Acad Sci U S A VL - 09 UR - https://doi.org/10.1073/pnas.1201105109 DO - 10.1073/pnas.1201105109 ID - Liu2012 ER - TY - JOUR AU - Glück, S. AU - Ross, J. S. AU - Royce, M. AU - McKenna, E. F. AU - Perou, C. M. AU - Avisar, E. PY - 2012 DA - 2012// TI - TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab JO - Breast Cancer Res Treat VL - 132 UR - https://doi.org/10.1007/s10549-011-1412-7 DO - 10.1007/s10549-011-1412-7 ID - Glück2012 ER - TY - JOUR AU - Shen, K. AU - Qi, Y. AU - Song, N. AU - Tian, C. AU - Rice, S. D. AU - Gabrin, M. J. PY - 2012 DA - 2012// TI - Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02–103 clinical trial JO - BMC Med Genomics VL - 5 UR - https://doi.org/10.1186/1755-8794-5-51 DO - 10.1186/1755-8794-5-51 ID - Shen2012 ER - TY - JOUR AU - Humbert, O. AU - Berriolo-Riedinger, A. AU - Riedinger, J. M. AU - Coudert, B. AU - Arnould, L. AU - Cochet, A. PY - 2012 DA - 2012// TI - Changes in 18 F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds071 DO - 10.1093/annonc/mds071 ID - Humbert2012 ER - TY - JOUR AU - Humbert, O. AU - Cochet, A. AU - Riedinger, J. M. AU - Berriolo-Riedinger, A. AU - Arnould, L. AU - Coudert, B. PY - 2014 DA - 2014// TI - HER2-positive breast cancer: 18 F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy JO - Eur J Nucl Med Mol Imaging VL - 41 UR - https://doi.org/10.1007/s00259-014-2739-1 DO - 10.1007/s00259-014-2739-1 ID - Humbert2014 ER - TY - JOUR AU - Jones, S. E. AU - Collea, R. AU - Paul, D. AU - Sedlacek, S. AU - Favret, A. M. AU - Gore, I. PY - 2013 DA - 2013// TI - Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70384-X DO - 10.1016/S1470-2045(13)70384-X ID - Jones2013 ER - TY - JOUR AU - Lara, P. N. AU - Laptalo, L. AU - Longmate, J. AU - Lau, D. H. AU - Gandour-Edwards, R. AU - Gumerlock, P. H. PY - 2004 DA - 2004// TI - California Cancer Consortium. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial JO - Clin Lung Cancer VL - 5 UR - https://doi.org/10.3816/CLC.2004.n.004 DO - 10.3816/CLC.2004.n.004 ID - Lara2004 ER - TY - JOUR AU - Yan, Y. AU - Lu, L. AU - Liu, C. AU - Li, W. AU - Liu, T. AU - Fu, W. PY - 2015 DA - 2015// TI - HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis JO - Clin Res Hepatol Gastroenterol. VL - 39 UR - https://doi.org/10.1016/j.clinre.2014.06.019 DO - 10.1016/j.clinre.2014.06.019 ID - Yan2015 ER - TY - JOUR AU - Dai, G. H. AU - Shi, Y. AU - Chen, L. AU - Lv, Y. L. AU - Zhong, M. PY - 2012 DA - 2012// TI - Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression JO - Hepatogastroenterology VL - 59 ID - Dai2012 ER - TY - JOUR AU - Crown, J. AU - Kennedy, M. J. AU - Tresca, P. AU - Marty, M. AU - Espie, M. AU - Burris, H. A. PY - 2013 DA - 2013// TI - Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt222 DO - 10.1093/annonc/mdt222 ID - Crown2013 ER -